Primary hyperparathyroidism is a hormonal condition that causes the tiny parathyroid glands in the neck to produce too much parathyroid hormone, leading to elevated calcium levels in the blood. While many people experience no symptoms and are diagnosed during routine blood tests, others may develop bone thinning, kidney stones, or other complications if left untreated.

Pathways to Controlling Overactive Parathyroid Glands

The main goal of treating primary hyperparathyroidism is to bring calcium levels back to normal and prevent long-term complications that affect the bones, kidneys, and other organs. Treatment decisions depend heavily on whether a person has symptoms, how high their calcium levels are, and whether complications have already developed. Some people with very mild disease and no symptoms may not need immediate treatment, while others require prompt intervention to avoid serious health problems.^[1]

Medical societies and expert panels have developed detailed guidelines to help doctors decide who needs treatment right away and who can be safely monitored over time. These recommendations take into account factors such as age, bone density, kidney function, and calcium levels. The approach to treatment has evolved significantly over the past few decades, as doctors now catch the condition much earlier through routine blood testing before serious complications occur.^[4]

Beyond the established surgical and medical approaches that have been used for years, researchers are actively exploring new therapies through clinical trials. These investigational treatments aim to offer alternatives for patients who cannot undergo surgery or who need additional options to control their calcium levels. Understanding both standard and emerging treatments helps patients and doctors work together to choose the best path forward.

Standard Surgical and Medical Treatment Options

Surgery to remove one or more overactive parathyroid glands, called parathyroidectomy, is considered the definitive treatment for primary hyperparathyroidism. This procedure offers the only complete cure for the condition. When performed by experienced endocrine surgeons, parathyroidectomy has success rates ranging from 90 to 95 percent, with a low rate of complications.^[4]

In most cases, the cause of primary hyperparathyroidism is a single noncancerous growth called an adenoma on one of the four parathyroid glands. During surgery, the surgeon removes the affected gland or glands. In about 85 percent of patients, only one gland is affected and needs to be removed. Less commonly, all four parathyroid glands become enlarged (a condition called hyperplasia), and the surgeon may need to remove more tissue. Fewer than 0.5 percent of cases are caused by parathyroid cancer, which requires more extensive surgery.^[4]

Before surgery, doctors use imaging tests to locate the overactive gland. These may include ultrasound scans, computed tomography (CT) scans, or specialized nuclear medicine tests that help pinpoint which gland is causing the problem. This pre-operative imaging helps surgeons plan the procedure and can sometimes allow for a smaller, more focused operation rather than exploring all four glands.^[3]

For patients who cannot have surgery or choose not to undergo the procedure, medical management with medications is an alternative. The most commonly used medications for primary hyperparathyroidism belong to a class called calcimimetics. These drugs work by making the calcium-sensing receptors on the parathyroid glands more sensitive to calcium in the blood. When the receptors become more sensitive, the glands respond by producing less parathyroid hormone, which in turn lowers blood calcium levels.^[11]

The most studied calcimimetic drug is cinacalcet. This medication has been shown to reduce calcium levels and parathyroid hormone levels in patients with primary hyperparathyroidism. However, it is important to understand that calcimimetics do not cure the disease—they only control calcium levels while the medication is being taken. Once the drug is stopped, calcium and hormone levels typically rise again.^[11]

Another class of medications sometimes used in the management of primary hyperparathyroidism are bisphosphonates. These drugs, which include medications like alendronate, help preserve bone density by slowing down the breakdown of bone tissue. While bisphosphonates do not lower calcium levels or treat the underlying hormone imbalance, they can be helpful for patients with osteoporosis related to hyperparathyroidism who are not having surgery. They work by inhibiting the cells that break down bone, helping to maintain bone strength and reduce fracture risk.^[11]

The duration of medical treatment varies depending on individual circumstances. Some patients may use medications for many years if surgery is not an option. Others might use them as a temporary measure while preparing for surgery or while other medical conditions are being optimized. Regular monitoring of calcium levels, parathyroid hormone, kidney function, and bone density is essential for anyone on long-term medical management.

Potential side effects of calcimimetics include nausea, vomiting, and low calcium levels if the dose is too high. Bisphosphonates can cause digestive upset, bone and muscle pain, and rarely, more serious complications affecting the jaw or unusual fractures with very long-term use. Doctors carefully balance the benefits and risks when prescribing these medications and adjust doses based on blood test results and how well the patient tolerates them.^[11]

Emerging Therapies and Clinical Trial Approaches

While surgery remains the gold standard and calcimimetics offer a medical option, researchers continue to investigate new treatments for primary hyperparathyroidism through clinical trials. These studies test innovative approaches that may one day provide additional choices for patients, particularly those who cannot undergo surgery or do not respond adequately to current medications.

Clinical trials for primary hyperparathyroidism typically progress through several phases. Phase I trials focus primarily on safety—researchers carefully test a new drug or treatment in a small group of people to understand how the body processes it, what doses are safe, and what side effects might occur. Phase II trials expand to a larger group and begin to evaluate whether the treatment actually works to lower calcium levels or reduce parathyroid hormone production. Phase III trials compare the new treatment directly with current standard treatments in an even larger group of patients, providing the strongest evidence about effectiveness and safety.^[9]

One area of active research involves developing more selective and potent calcimimetic drugs. Newer versions of these medications aim to provide better calcium control with fewer side effects than the currently available options. These next-generation calcimimetics work through the same basic mechanism—making the parathyroid glands more sensitive to calcium signals—but may be engineered to work more specifically on parathyroid tissue or to have longer-lasting effects that require less frequent dosing.

Another research direction explores whether certain medications that affect bone metabolism might help manage primary hyperparathyroidism. Scientists are studying how drugs that influence the way bones respond to parathyroid hormone might protect bone density in patients with the condition. While these approaches would not address the root cause of excessive hormone production, they might prevent one of the major complications of the disease—bone thinning and increased fracture risk.

Some clinical trials are investigating whether vitamin D supplementation or other nutritional interventions might play a role in managing mild primary hyperparathyroidism. Interestingly, many patients with primary hyperparathyroidism also have low vitamin D levels, and researchers are exploring whether correcting this deficiency affects disease progression or symptoms. These studies examine how vitamin D therapy influences calcium levels, parathyroid hormone secretion, and bone health over time.^[3]

Eligibility for clinical trials varies depending on the specific study. Most trials have strict criteria about factors such as calcium levels, severity of disease, age, and whether other treatments have been tried. Some trials specifically seek patients who have not had surgery, while others may enroll patients after unsuccessful surgical treatment. Geographic location also matters—trials may be conducted at specific medical centers in the United States, Europe, or other regions, and patients typically need to be able to travel to the study site for regular monitoring visits.^[9]

Preliminary results from some clinical trials testing newer calcimimetic drugs have shown promising ability to lower calcium levels in patients with primary hyperparathyroidism. Some studies have reported reductions in parathyroid hormone levels along with improvements in calcium measurements. Early safety profiles from these studies suggest that newer drugs may be well-tolerated, though longer-term data is still being collected. These results, while encouraging, are still considered preliminary until larger Phase III trials confirm the findings.^[11]

Research is also exploring whether certain patients might benefit from combination approaches—using two or more treatments together to achieve better calcium control. For example, scientists are studying whether combining a calcimimetic drug with a medication that protects bone density produces better outcomes than either treatment alone. These combination strategies attempt to address both the hormone imbalance and its effects on target organs like bone.

Most common treatment methods

• Parathyroidectomy (surgical removal of parathyroid glands)
  • The definitive cure for primary hyperparathyroidism, with success rates of 90-95% when performed by experienced surgeons
  • Typically involves removing one overactive gland (adenoma) or, less commonly, multiple enlarged glands
  • Pre-operative imaging with ultrasound or CT scans helps locate the affected gland
  • Considered the treatment of choice for patients with symptoms or complications
• Calcimimetic medications
  • Cinacalcet is the most studied drug in this class
  • Works by making calcium-sensing receptors on parathyroid glands more sensitive to blood calcium
  • Reduces both calcium levels and parathyroid hormone production
  • Does not cure the disease; levels return to abnormal when medication is stopped
  • May cause side effects including nausea, vomiting, and low calcium if dose is too high
• Bisphosphonate therapy
  • Includes medications like alendronate
  • Helps preserve bone density by slowing bone breakdown
  • Does not lower calcium levels or treat the hormone imbalance
  • Useful for patients with osteoporosis related to hyperparathyroidism who are not having surgery
  • Potential side effects include digestive upset and bone/muscle pain
• Watchful waiting with regular monitoring
  • Appropriate for some patients with mild disease and no symptoms
  • Requires commitment to regular blood tests, bone density scans, and kidney function monitoring
  • Surgery recommended if calcium rises further, bone density declines, or complications develop
  • Not suitable for all patients—specific criteria must be met